Instructions for Farisil sore throat spray for the oral cavity 1.5 mg/ml with lemon flavor 30 ml
Composition
active ingredient: benzydamine hydrochloride;
1 ml of oral spray contains 1.5 mg of benzydamine hydrochloride;
excipients: saccharin, sodium bicarbonate, polysorbate 20, "Mint" or "Lemon" flavoring, methyl parahydroxybenzoate (E 218), glycerin, ethanol 96%, purified water.
Dosage form
Mouth spray with mint or lemon flavor.
Main physicochemical properties: clear colorless liquid with a characteristic odor and taste of mint or lemon.
Pharmacotherapeutic group
Means for use in dentistry. Other means for local use in the oral cavity. ATX code A01A D02.
Pharmacological properties
Pharmacodynamics.
Benzydamine is a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and antiexudative properties.
In clinical trials, benzydamine has been shown to be effective in relieving symptoms associated with localized irritant pathologies in the oral cavity and pharynx. In addition, benzydamine has anti-inflammatory and local analgesic effects, and has a local anesthetic effect on the oral mucosa.
Pharmacokinetics.
The fact of absorption through the mucous membrane of the oral cavity and pharynx has been proven by the presence of measurable amounts of benzydamine in human blood plasma. However, this is not sufficient to detect any systemic pharmacological effect. Excretion occurs mainly in the urine, mainly in the form of inactive metabolites or conjugated compounds.
It has been shown that topical application achieves the accumulation of effective concentrations of benzydamine in inflamed tissues due to its ability to penetrate the mucous membrane.
Indication
Symptomatic treatment of irritations and inflammations of the oropharynx; pain caused by gingivitis, stomatitis, pharyngitis; in dentistry after tooth extraction or for prophylactic purposes.
Contraindication
Hypersensitivity to the active substance or to other components of the drug.
Interaction with other medicinal products and other types of interactions
Interaction studies have not been conducted.
Application features
If sensitivity occurs during long-term use, treatment should be discontinued and a doctor should be consulted to prescribe appropriate treatment.
In some patients, buccal/pharyngeal ulcers may be due to serious pathological processes. Therefore, patients whose symptoms worsen or do not improve within 3 days, or who develop a fever or other symptoms, should seek advice from a general practitioner or dentist as appropriate.
Benzydamine is not recommended for use in patients with hypersensitivity to acetylsalicylic acid or other NSAIDs.
The use of the drug may cause bronchospasm in patients with bronchial asthma or in patients with a history of bronchial asthma. Such patients should be warned about this.
This medicine contains a small amount of ethanol (alcohol), less than 100 mg/dose.
For athletes: the use of medicines containing ethyl alcohol may give a positive result in an anti-doping test, taking into account the limits set by some sports federations.
The drug contains methyl parahydroxybenzoate (methylparaben), which may cause allergic reactions (possibly delayed), and in some cases, bronchospasm.
Use during pregnancy or breastfeeding
There are currently no adequate data available on the use of benzydamine in pregnant or breastfeeding women. The ability of this drug to pass into breast milk has not been studied. Animal data are insufficient to draw any conclusions regarding the effects of this drug during pregnancy or breastfeeding. The potential risk to humans is unknown.
FARISIL SORE THROAT SPRAY should not be used during pregnancy or breastfeeding.
Ability to influence reaction speed when driving vehicles or other mechanisms
When used in recommended doses, the drug has no effect on the ability to drive vehicles and work with other mechanisms.
Method of administration and doses
Before use, the spraying device must be installed.
When you press the spray device, a spray is formed, which contains 1 dose - 0.17 ml, which corresponds to 0.255 mg of benzydamine hydrochloride.
Dosage
Adults: 4–8 sprays 2–6 times daily.
Children (6–12 years): 4 sprays 2–6 times daily.
Children (4–6 years): 1 spray for every 4 kg of body weight, up to a maximum dose equivalent to 4 sprays, 2–6 times daily.
Do not exceed recommended dosages.
Children.
The drug can be used in children aged 4 years and over.
Overdose
Accidental ingestion of large amounts of benzydamine (> 300 mg), especially in children, may result in poisoning. Characteristic signs of overdose are gastrointestinal symptoms (most often nausea, vomiting, abdominal pain, esophageal irritation) and central nervous system symptoms (dizziness, hallucinations, agitation, convulsions, tremor, increased sweating, ataxia, anxiety, and irritability).
Such acute overdose requires immediate gastric lavage, treatment of water and electrolyte imbalances and symptomatic treatment, adequate hydration.
Adverse reactions
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Adverse reactions are classified according to frequency of occurrence: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); frequency unknown (cannot be estimated from the available data).
Gastrointestinal: rarely - burning sensation in the mouth, dry mouth; frequency unknown - oral hypoesthesia, nausea, vomiting, swelling and discoloration of the tongue, taste changes.
On the part of the immune system: rarely - hypersensitivity reaction; frequency unknown - anaphylactic reaction.
Respiratory, thoracic and mediastinal disorders: very rarely - laryngospasm; frequency unknown - bronchospasm.
Skin and subcutaneous tissue disorders: uncommon - photosensitivity; very rare - angioedema; frequency unknown - rash, itching, urticaria.
Nervous system: frequency unknown - dizziness, headache.
Reporting of suspected adverse reactions
Reporting adverse reactions after registration of a medicinal product is of great importance. This allows monitoring of the benefit/risk ratio when using this medicinal product. Medical and pharmaceutical professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of a medicinal product via the Automated Information System for Pharmacovigilance at the link: https://aisf.dec.gov.ua
Expiration date
3 years.
Do not use the drug after the expiration date indicated on the package.
Storage conditions
Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Packaging
30 ml in a container with a lid, complete with a spray device in a pack.
Vacation category
Without a prescription.
Producer
Joint Ukrainian-Spanish enterprise "Sperco Ukraine".
Location of the manufacturer and address of its place of business.
21027, Ukraine, Vinnytsia, 600-anniversary St., 25.
Phone: + 38(0432)52-30-36. E-mail: trade@sperco.com.ua
www.sperco.ua
